Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies.

Thumbnail Image

Files

Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies.pdf (655.17 KB)

Embargo End Date

ICR Authors

Cheang, Chon
 Bliss, Judith
 Kilburn, Lucy

Authors

Cheang, MCU
Rimawi, M
Johnston, S
Jacobs, SA
Bliss, J
Pogue-Geile, K
Kilburn, L
Zhu, Z
Schuster, EF
Xiao, H
Swaim, L
Deng, S
Lu, DR
Gauthier, E
Tursi, J
Slamon, DJ
Rugo, HS
Finn, RS
Liu, Y

Document Type

Journal Article

Date

2024-06-29

Date Accepted

2024-06-14

Abstract

Intrinsic breast cancer molecular subtyping (IBCMS) provides significant prognostic information for patients with breast cancer and helps determine treatment. This study compared IBCMS methods on various gene-expression platforms in PALOMA-2 and PALLET trials. PALOMA-2 tumor samples were profiled using EdgeSeq and nanostring and subtyped with AIMS, PAM50, and research-use-only (ruo)Prosigna. PALLET tumor biopsies were profiled using mRNA sequencing and subtyped with AIMS and PAM50. In PALOMA-2 (n = 222), a 54% agreement was observed between results from AIMS and gold-standard ruoProsigna, with AIMS assigning 67% basal-like to HER2-enriched. In PALLET (n = 224), a 69% agreement was observed between results from PAM50 and AIMS. Different IBCMS methods may lead to different results and could misguide treatment selection; hence, a standardized clinical PAM50 assay and computational approach should be used.Trial number: NCT01740427.

Citation

npj Breast Cancer, 2024, 10 (1), pp. 54 -

DOI

10.1038/s41523-024-00658-y
10.1038/s41523-024-00658-y

URI

https://repository.icr.ac.uk/handle/internal/6351

Rights

http://creativecommons.org/licenses/by/4.0/

Source Title

npj Breast Cancer

Publisher

NATURE PORTFOLIO

ISSN

2374-4677

eISSN

2374-4677
2374-4677

Collections

Clinical Studies

Research Team

Clin Trials & Stats Unit

Notes